These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Thromboembolic complications of intravenous immunoglobulin treatment. Vucic S; Chong PS; Dawson KT; Cudkowicz M; Cros D Eur Neurol; 2004; 52(3):141-4. PubMed ID: 15479982 [TBL] [Abstract][Full Text] [Related]
5. A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy. Zinman LH; Sutton D; Ng E; Nwe P; Ngo M; Bril V Transfus Apher Sci; 2005 Nov; 33(3):317-24. PubMed ID: 16239123 [TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin, blood viscosity and myocardial infarction. Fisman DN; Smilovitch M Can J Cardiol; 1997 Aug; 13(8):775-7. PubMed ID: 9284845 [TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Cornblath DR; Chaudhry V; Griffin JW Ann Neurol; 1991 Jul; 30(1):104-6. PubMed ID: 1929221 [TBL] [Abstract][Full Text] [Related]
8. Analysis of thromboembolic risk related to high-dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases. Mignogna MD; Fortuna G; Leuci S; Ruoppo E; Adamo D; Fedele S Clin Exp Dermatol; 2009 Mar; 34(2):145-50. PubMed ID: 19187294 [TBL] [Abstract][Full Text] [Related]
9. Acute myocardial infarction following intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy in association with a monoclonal immunoglobulin G paraprotein. Stamboulis E; Theodorou V; Kilidireas K; Apostolou T Eur Neurol; 2004; 51(1):51. PubMed ID: 14639034 [No Abstract] [Full Text] [Related]
10. Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study. Rajabally YA; Kearney DA J Neurol Sci; 2011 Sep; 308(1-2):124-7. PubMed ID: 21679973 [TBL] [Abstract][Full Text] [Related]
11. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749 [TBL] [Abstract][Full Text] [Related]
12. Chronic inflammatory demyelinating polyneuropathy in a diabetic patient: deterioration after intravenous immunoglobulins treatment and favorable response to steroid treatment. Pedersen K; Pandolfo M; Mavroudakis N Acta Neurol Belg; 2007 Mar; 107(1):14-7. PubMed ID: 17569228 [TBL] [Abstract][Full Text] [Related]
14. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. Misbah SA; Baumann A; Fazio R; Dacci P; Schmidt DS; Burton J; Sturzenegger M J Peripher Nerv Syst; 2011 Jun; 16(2):92-7. PubMed ID: 21692906 [TBL] [Abstract][Full Text] [Related]
15. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Hefer D; Jaloudi M Ann Hematol; 2004 Oct; 83(10):661-5. PubMed ID: 15309520 [TBL] [Abstract][Full Text] [Related]
20. A subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIg. Caro XJ; Winter EF; Dumas AJ Rheumatology (Oxford); 2008 Feb; 47(2):208-11. PubMed ID: 18208823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]